Evidence Synthesis
JAGSNPHARM's 63.66% accelerated to, up from 13.77% in the previous quarter.
The company's moved to a decelerating trend, down from 15%. Revenue growth slowed to from 23.8%. The INR declined to, down from 238.72 INR in the previous day. Daily trading volume dropped to shares, a decrease from 339859 shares.
By paying you agree to our Terms and Privacy Policy.